Vimarsana
Biggest News Aggregation in the World

Morphosys Us Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys Us Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Us Inc Today - Breaking & Trending Today

Wells Fargo Predicts up to 125% Rally for These 2 Stocks — Here's Why They Have Solid Upside - Vimarsana News

Wells Fargo Predicts up to 125% Rally for These 2 Stocks — Here's Why They Have Solid Upside

Even accounting for recent losses, the tech-heavy NASDAQ index is up 28% so far this year, leading the way in an overall bullish market. The surge in the NASDAQ has been fueled by investors gravitating towards tech giants. According to Chris Harvey, head of equity strategy for Wells Fargo, the rally is solid, and it will remain so until the Federal Reserve cranks up interest rates enough to kill it. Harvey notes that inflation, while falling, remains persistently above the central bank’s 2% targ

Source: yahoo.com
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses - Vimarsana News

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...

Tafasitamab Combination Provides Prolonged, Durable Response in Patients with Aggressive DLBCL - Vimarsana News

Tafasitamab Combination Provides Prolonged, Durable Response in Patients with Aggressive DLBCL

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) - Vimarsana News

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023

Incyte and MorphoSys U.S. Inc.: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) - Vimarsana News

Incyte and MorphoSys U.S. Inc.: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary